Published in Medical Letter on the CDC and FDA, January 14th, 2007
The company established its sales force in early 2005 in anticipation of a product launch for Entereg (alvimopan) for the management of postoperative ileus later that year. The recent Food and Drug Administration (FDA) approvable letter and subsequent delay to possible market entry for the company's lead product Entereg was the impetus for the decision. The sales force has been detailing GlaxoSmithKline's (GSK) anti-thrombotic agent Arixtra under its co-promotion agreement with GSK, which expired on December 31,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.